超声引导下经皮微波消融治疗子宫肌瘤的中期局部治疗疗效及相关影响因素
回顾性纳入2020年7月至2021年10月接受超声引导下经皮微波消融的28例患者共52个子宫肌瘤,分析术前临床特征、常规超声及超声造影特征与3个月随访体积缩小率≥50%的相关性;术后1、3、6个月中位体积缩小率分别为30.1%、46.9%、65.8%,3个月时44.4%肌瘤达到充分消融,术前超声造影早期非增强区与充分消融相关(p<0.05)。
要点
- 术后1、3、6个月子宫肌瘤中位体积缩小率分别为30.1%、46.9%、65.8%。
- 3个月随访时44.4%肌瘤达到充分消融(体积缩小率≥50%),55.6%为部分消融。
- 术前超声造影早期(注射造影剂后30秒内)非增强区与3个月充分消融相关(p<0.05)。
核心结论
- 超声引导下经皮微波消融是治疗子宫肌瘤有效且安全的方法;术前超声造影早期非增强区与中期局部治疗疗效相关,可能用于预测治疗转归。
研究设计与样本
- 回顾性纳入2020年7月至2021年10月接受超声引导下经皮微波消融的28例患者共52个子宫肌瘤,分析术前临床特征、常规超声及超声造影特征与3个月随访体积缩小率≥50%的相关性。
关键影像表现/征象
- 术前超声造影早期(注射造影剂后30秒内)非增强区见于22.2%的子宫肌瘤。
- 术后1、3、6个月随访子宫肌瘤中位体积缩小率分别为30.1%、46.9%、65.8%。
- 所有患者的相关临床症状缓解或消失。
诊断标准与关键数值
- 充分消融定义为3个月随访时体积缩小率至少50%,3个月随访时44.4%的肌瘤达到充分消融。
- 部分消融定义为体积缩小率<50%,3个月随访时55.6%的肌瘤为部分消融。
- 术前超声造影早期(注射造影剂后30秒内)非增强区与3个月随访充分消融相关(p<0.05)。
- 微波消融后子宫肌瘤症状评分与生活质量评分较微波消融后下降(p=0.04和p=0.057)。
临床应用与阅片要点
- 术前超声造影早期(注射造影剂后30秒内)非增强区可能用于预测子宫肌瘤微波消融的中期局部治疗转归。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the mid-term local treatment efficiency of ultrasound-guided percutaneous microwave ablation (MWA) for uterine fibroids (UFs) and the associated influencing factors.
METHODS: From July 2020 to October 2021, a total of 28 patients with 52 UFs who had undergone ultrasound-guided MWA were retrospectively included in this study. Pre-treatment clinical characteristics, conventional ultrasound and contrast-enhanced ultrasound (CEUS) features were analyzed to explore their correlation with volume reduction ratios (VRRs) of sufficient ablation (i.e. a VRR of at least 50% at the 3 month follow-up). The patients were assessed at 1-, 3-, 6 month follow-up after MWA treatment and the assessment included VRR, adverse events, uterine fibroid symptom (UFS) and quality of life (QoL) scores, and clinical symptoms.
RESULTS: The procedures of percutaneous MWA for UFs were tolerated well and no major complications occurred in all patients. At the 1-, 3-, 6 month follow-up, the median VRRs of UFs were 30.1%, 46.9%, and 65.8%, respectively. At the 3 month follow-up, 44.4% of fibroids obtained sufficient ablation while the remaining 55.6% obtained partial ablation (i.e. a VRR of <50%). Non-enhancing area during the early phase (i.e. within 30 s after injecting contrast agent) on pre-treatment CEUS was present in 22.2% UFs, which was associated with sufficient ablation at the 3 month follow-up (p < 0.05). In addition, the relevant clinical symptoms of all patients were alleviated or removed. The UFS and QoL score after MWA decreased significantly in comparison with those after MWA (p = 0.04 and p = 0.057, respectively), indicating a remarkable improvement of clinical symptom and QoL.
CONCLUSION: Ultrasound-guided MWA is an effective and safe method to treat patients with UFs. Non-enhancing area during the early phase on pretreatment CEUS is associated with mid-term local treatment efficiency, which might be used to predict treatment outcome.
ADVANCES IN KNOWLEDGE: Non-enhancing area during the early phase on pretreatment CEUS is an important factor associated with mid-term local treatment efficiency. This is the first study finding that CEUS feature can be used as a marker for the prediction of mid-term local treatment response.
引用
- Li, Li, Deng, et al. Ultrasound-guided percutaneous microwave ablation for uterine fibroids: mid-term local treatment efficiency and associated influencing factors. Br J Radiol. 2022. PMID: 35762323. doi:10.1259/bjr.20220039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。